Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Non-Hodgkin 7Lymphoma, B-Cell 5Lymphoma 3Recurrence 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Hodgkin Disease 2Burkitt Lymphoma 2Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

pembrolizumab 39Bevacizumab 25Cyclophosphamide 23Blood Specimen Collection 19Standard of Care 17Nivolumab 17Carboplatin 17Paclitaxel 15Exercise 15Gemcitabine 14atezolizumab 13Pemetrexed 13Cisplatin 13Radiotherapy 11Fluorouracil 11Doxorubicin 11Cetuximab 10130-nm albumin-bound paclitaxel 10durvalumab 9Rituximab 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9Biopsy 9abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Prednisone 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × polatuzumab vedotin × 90 days × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡